Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Cellular Biomedicine Group (CBMG)

Request full access

A clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancers and stem cell therapies

North Potomac, United StatesFounded 2009Biotech & Life Sciences

About Cellular Biomedicine Group (CBMG)

Cellular Biomedicine Group (CBMG), which rebranded as AbelZeta Pharma, Inc. in November 2023, is a clinical-stage biopharmaceutical firm focused on developing cell therapies for cancer and autoimmune diseases. The company was founded in 2009 by a team of Chinese-American executives and scientists. A key figure in its history is Dr. Wei (William) Cao, one of the founding executives who joined in 2010 and later became CEO. Another pivotal leader is Tony (Bizuo) Liu, who, with a robust background in finance and corporate strategy from roles at Microsoft and Alibaba, joined CBMG's board in 2013, became CFO in 2014, and has served as CEO since 2016. After trading on NASDAQ, the company completed a privatization process in February 2021, led by a consortium including company management and several investment funds.

The company's business model is centered on its proprietary cell-based technology platforms, particularly Chimeric Antigen Receptor T-cell (CAR-T) and Tumor-Infiltrating Lymphocyte (TIL) therapies. Revenue is primarily generated through strategic licensing, collaboration agreements, and milestone payments with major pharmaceutical companies. A landmark event was a May 2023 global collaboration with Janssen Biotech (a Johnson & Johnson company), which included a $245 million upfront payment to develop and commercialize next-generation CAR-T therapies. The company also has manufacturing and supply agreements, such as one with Novartis for the CAR-T therapy Kymriah in China. CBMG operates state-of-the-art GMP-certified manufacturing facilities in both Rockville, Maryland, and Shanghai to support its clinical trials in the U.S. and China.

CBMG’s product pipeline targets treatments for various cancers and degenerative diseases. A leading candidate is C-CAR039, a bispecific CAR-T therapy targeting CD19 and CD20 for B-cell malignancies, which has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. FDA. Another key product is C-CAR066, an anti-CD20 CAR-T therapy. The company is also developing treatments for solid tumors, such as AFP TCR-T for liver cancer and TIL therapies for non-small cell lung cancer. Previously, its portfolio included stem cell therapies for Knee Osteoarthritis, such as AlloJoin® and ReJoin®, which were later spun off to sharpen the company's focus on immune-oncology.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2007
Employees
6
Open positions
None listed
Dealroom signal
59.2/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Biomedical, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Sep 2021 $120M $480M CICC · GIC · TF Capital · Sequoia —
POST IPO EQUITYOther financing Feb 2018 $31M — Sailing Capital —
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Cellular Biomedicine Group (CBMG) website traffic

Latest recorded traffic for Cellular Biomedicine Group (CBMG) is 180 monthly website visits, down 40% over the last three months. Cellular Biomedicine Group (CBMG)'s team grew 0% over the past year.

Latest monthly visits180 3-month web change-40% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom
1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Cellular Biomedicine Group (CBMG) in the North Potomac ecosystem

Live from Dealroom

The Cellular Biomedicine Group (CBMG) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A7 investors entered at this stage

Series B and later1 investor entered at this stage

  • Sailing Capital

Other known investors1 additional known investor

  • Funcity Capital
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · North Potomac HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Cellular Biomedicine Group (CBMG) on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cellular Biomedicine Group (CBMG)’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.